Altimmune Presents Data Sunday From Phase 2 MOMENTUM Trial Of Pemvidutide In Obesity During Oral Presentation At American Diabetes Association's 84th Scientific Sessions
Portfolio Pulse from Benzinga Newsdesk
Altimmune, Inc. (NASDAQ:ALT) presented data from its Phase 2 MOMENTUM trial of pemvidutide in obesity at the American Diabetes Association's 84th Scientific Sessions. The trial showed significant weight loss and improvements in body composition, serum lipids, and blood pressure without major cardiac issues.
June 23, 2024 | 6:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Altimmune presented positive Phase 2 trial results for pemvidutide, showing significant weight loss and health improvements in obese subjects. This could boost investor confidence and positively impact the stock price.
The positive results from the Phase 2 trial of pemvidutide, including significant weight loss and health improvements, are likely to boost investor confidence in Altimmune. The lack of major cardiac issues further strengthens the potential of pemvidutide as a viable treatment for obesity, which could lead to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100